Top Page
Advanced Medical Solutions
(LSE:AMS)
Advanced Medical Solutions (AMS) vs. iShares MSCI United Kingdom ETF (EWC)
Advanced Medical Solutions Business Overview & Revenue Model
Advanced Medical Solutions Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 220.30M | 177.52M | 126.21M | 124.33M | 108.60M | 86.80M |
| Gross Profit | 108.40M | 82.77M | 70.14M | 68.62M | 56.12M | 42.67M |
| EBITDA | 37.81M | 29.68M | 31.40M | 34.94M | 31.55M | 17.53M |
| Net Income | 9.17M | 7.09M | 15.89M | 20.41M | 17.48M | 8.58M |
Balance Sheet | ||||||
| Total Assets | 397.44M | 389.00M | 289.17M | 281.09M | 249.51M | 238.56M |
| Cash, Cash Equivalents and Short-Term Investments | 19.34M | 17.04M | 60.16M | 82.26M | 72.97M | 53.83M |
| Total Debt | 82.38M | 86.56M | 9.14M | 9.75M | 9.86M | 11.12M |
| Total Liabilities | 140.50M | 147.48M | 44.97M | 44.47M | 36.83M | 36.34M |
| Stockholders Equity | 256.24M | 240.78M | 244.20M | 236.62M | 212.68M | 202.21M |
Cash Flow | ||||||
| Free Cash Flow | 19.17M | 12.67M | 2.50M | 17.12M | 23.95M | 15.79M |
| Operating Cash Flow | 24.04M | 16.73M | 12.35M | 27.08M | 30.41M | 21.05M |
| Investing Cash Flow | -65.83M | -67.15M | -20.27M | -12.70M | -6.41M | -27.05M |
| Financing Cash Flow | -70.55M | 5.48M | -13.62M | -5.70M | -4.41M | -5.09M |
Advanced Medical Solutions Technical Analysis
Advanced Medical Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | £174.28M | 26.22 | 20.31% | 3.82% | 10.80% | 1.75% | |
| ― | £4.81B | 29.84 | 12.73% | 2.06% | 4.18% | 37.65% | |
| ― | £466.95M | 51.29 | 3.66% | 1.23% | 68.03% | -18.27% | |
| ― | £324.82M | 9.41 | 15.04% | ― | 1231.50% | ― | |
| ― | £402.76M | -11.27 | ― | ― | 4.50% | 74.32% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Advanced Medical Solutions Corporate Events
Study Overview: Advanced Medical Solutions is conducting a study titled ‘Long-Term Safety and Efficacy Evaluation of Seal-G and Seal-G MIST Surgical Sealants for Anastomosis Protection in Colon Surgery.’ The study aims to assess the long-term safety and effectiveness of Seal-G/MIST surgical sealants in reducing postoperative complications in colon anastomosis surgeries, such as leaks and obstructions, over a period exceeding 12 months.
Advanced Medical Solutions (GB:AMS) is conducting a post-approval study titled Post Approval Study to Evaluate the Safety and Performance of GENTA-FOIL Resorb® for the Prevention of Tissue Adhesions in Hand Surgery. The study aims to assess the safety and effectiveness of Genta-Foil resorb®, a device designed to prevent tissue adhesions following hand surgery, highlighting its significance in improving surgical outcomes.
Study Overview: Advanced Medical Solutions is conducting a study titled Study of the Osteoconductive Potential of the Injectable Bone Substitute In’Oss™ (MBCP® Putty) in the Filling of Orthopaedic Bone Defects. The study aims to evaluate the osteoconductive potential of In’Oss™ (MBCP® Putty), a CE-marked device, in filling orthopedic bone defects, particularly in trauma surgery. This research is significant for collecting Post-Market Clinical Follow-up data, which is crucial for the device’s continued market approval and use.
Advanced Medical Solutions (GB:AMS) is conducting a post-market surveillance study titled Post-market Surveillance Study to Confirm the Safety and Performance of Silver I Alginate Non-Woven Dressing (Hydro-Alginate) in Chronic and Acute Wounds. The study aims to verify the safety and effectiveness of the Silver I Alginate Non-Woven Dressing in treating both chronic and acute wounds, which is significant for ensuring ongoing product reliability and patient safety.
Study Overview: Advanced Medical Solutions is conducting a Post Market Surveillance Study titled ‘Post Market Surveillance Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds.’ The study aims to validate the safety and effectiveness of the Silver II Non-woven Dressing in treating chronic and acute wounds, emphasizing its significance in wound care management.
Advanced Medical Solutions Group plc has announced its participation in upcoming investor conferences in November and December, including the Investec UK CEO Conference and the Berenberg European Conference. These events will provide AMS with opportunities to engage with investors through one-on-one and group meetings, potentially enhancing its visibility and investor relations. The company’s strategic focus on expanding its market presence and leveraging synergies from recent acquisitions positions it for continued growth and value creation.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £221.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc announced a shareholding transaction involving Eddie Johnson, a Director and Chief Financial Officer, who sold and repurchased shares as part of normal tax planning. This transaction reflects internal financial adjustments and does not indicate any strategic shift, maintaining the company’s stable market position.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £221.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc announced its total voting rights, with an issued share capital comprising 219,380,303 ordinary shares as of September 30, 2025. This figure is relevant for shareholders to determine their notification requirements under the FCA’s Disclosure and Transparency Rules. The announcement reflects the company’s commitment to transparency and regulatory compliance, potentially impacting shareholder engagement and interest in the company.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £221.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc announced a shareholding transaction involving its CEO, Chris Meredith, who transferred 50,510 Ordinary Shares through sale and repurchase to various personal accounts, including Individual Savings Accounts and Self-Invested Personal Pensions. This transaction, which maintains the beneficial ownership of shares unchanged, is part of routine tax planning and does not impact the company’s operations or market positioning.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £221.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc reported strong interim results for the first half of 2025, with a 63% increase in group revenue to £110.8 million, driven by the acquisition of Peters Surgical and organic growth. The integration of Peters Surgical and Syntacoll has contributed positively, enhancing manufacturing efficiencies and expanding market presence, particularly in cardiovascular markets. Despite a slight reduction in gross margins, the company achieved a 42% increase in adjusted EBITDA and a 49% rise in profit before tax. The restructuring of the Woundcare business has been completed, positioning it as a cash-generative unit. AMS remains optimistic about sustaining growth, with plans for US product launches and further deleveraging by year-end.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £216.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc has applied to the London Stock Exchange for the block listing of 10,400,000 ordinary shares to be admitted to trading on AIM. This application involves shares issued under various company share schemes, with no change to the current issued share capital. The admission of these shares is expected to take effect on 15 September 2025, and they will rank equally with existing shares. This move is part of AMS’s ongoing strategy to support its growth and operational flexibility.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £221.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc announced its total issued share capital as of August 29, 2025, comprising 219,330,534 ordinary shares, each with voting rights, with no shares held in treasury. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £219.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc announced it will release its interim results for the first half of 2025 on September 17. The company will hold a briefing for analysts and a presentation for shareholders, highlighting its commitment to transparency and stakeholder engagement. This announcement underscores AMS’s ongoing efforts to maintain its strong market position and provide value to its investors.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £219.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc announced that its issued share capital as of July 31, 2025, consists of 219,288,700 ordinary shares with voting rights, with no shares held in treasury. This information is relevant for shareholders to determine their notification obligations under the FCA’s Disclosure and Transparency Rules. The announcement reflects AMS’s commitment to transparency and regulatory compliance, which may impact shareholder engagement and market perception.
The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.